Orfao A, Chillón M C, Bortoluci A M, López-Berges M C, García-Sanz R, Gonzalez M, Tabernero M D, García-Marcos M A, Rasillo A I, Hernández-Rivas J, San Miguel J F
Servicio General de Citometría, Hospital Universitario Salamanca, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain.
Haematologica. 1999 May;84(5):405-12.
Rapid identification of AML patients carrying the t(15;17) translocation for treatment decision-making is currently made on the basis of morphologic screening. However, the existence of both false positives and negatives highlights the need for more objective methods of screening AML cases and further molecular confirmation of the t(15;17) translocation.
In the present study we analyzed a total of 111 AML cases in order to investigate whether immunophenotyping based on the assessment of multiple-stainings analyzed at flow cytometry could improve the sensitivity and specificity of morphologic identification of acute promyelocytic leukemia (APL) carrying the t(15;17) translocation. FISH analysis was used as a complementary technique for cases in which morphology and molecular biology yielded discrepant results.
Concordant results between morphology and RT-PCR were found in 102/111 (91.8%) cases: 34 patients had M3/PML-RARalpha+ and 68 non-M3/PML-RARalpha- disease. Nine cases showed discrepants results. Multivariate analysis showed that the best combination of immunologic markers for discriminating between M3/PML-RARalpha+ and non-M3/PML-RARalpha- cases was that of the presence of heterogeneous expression of CD13, the existence of a single major blast cell population, and a characteristic CD34/CD15 phenotypic pattern (p<0.02). A score system based on these parameters was designed, and the 34 M3/PML-RARalpha+ cases showed a score of 3 (presence of the 3 phenotypic characteristics). In contrast, only 1 out of the 68 (1.3%) non-M3/PML-RARalpha- cases had this score, most o these latter cases (53/68, 78%) scoring either 0 or 1. Therefore, among these cases, immunophenotyping showed a sensitivity of 100% and a specificity of 99% for predicting PML/RARalpha gene rearrangements. Of the 9 cases in which morphology and molecular biology results were discrepant, four cases displayed M3 morphology without PML/RARalpha rearrangements by RT-PCR. In only one of these 4 cases did the immunophenotype score 3, this being the only FISH positive case. From the remaining five discrepant cases (non-M3 morphology while positive for PML/RARalpha) two cases had a phenotypic score of 3 and were FISH positive while the other three were negative by FISH. Upon repeating RT-PCR studies, two of these latter three cases became negative.
Our results show that immunophenotyping may be of great value for quick screening of APL with PML/RARalpha rearrangements.
目前,基于形态学筛查对携带t(15;17)易位的急性髓系白血病(AML)患者进行快速识别以用于治疗决策。然而,假阳性和假阴性的存在凸显了需要更客观的AML病例筛查方法以及对t(15;17)易位进行进一步分子确认的必要性。
在本研究中,我们共分析了111例AML病例,以研究基于流式细胞术分析的多染色评估的免疫表型分析是否能提高对携带t(15;17)易位的急性早幼粒细胞白血病(APL)形态学识别的敏感性和特异性。对于形态学和分子生物学结果不一致的病例,采用荧光原位杂交(FISH)分析作为补充技术。
102/111(91.8%)例形态学与逆转录聚合酶链反应(RT-PCR)结果一致:34例患者为M3/PML-RARα阳性,68例为非M3/PML-RARα阴性疾病。9例结果不一致。多变量分析表明,区分M3/PML-RARα阳性和非M3/PML-RARα阴性病例的最佳免疫标志物组合是CD13异质性表达的存在、单一主要母细胞群体的存在以及特征性的CD34/CD15表型模式(p<0.02)。基于这些参数设计了一个评分系统,34例M3/PML-RARα阳性病例得分为3(存在这3种表型特征)。相比之下,68例非M3/PML-RARα阴性病例中只有1例(1.3%)得此分数,这些后者病例中的大多数(53/68,78%)得分为0或1。因此,在这些病例中,免疫表型分析对预测PML/RARα基因重排的敏感性为100%,特异性为99%。在形态学和分子生物学结果不一致的9例病例中,4例表现为M3形态,但RT-PCR显示无PML/RARα重排。在这4例病例中只有1例免疫表型得分为3,这是唯一FISH阳性病例。在其余5例不一致病例(非M3形态但PML/RARα阳性)中,2例表型得分为3且FISH阳性,而另外3例FISH阴性。重复RT-PCR研究后,后3例中的2例变为阴性。
我们的结果表明,免疫表型分析对于快速筛查伴有PML/RARα重排的APL可能具有重要价值。